Unknown

Dataset Information

0

Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies.

ABSTRACT: Neutralizing antibodies (nAbs) that target the SARS-CoV-2 spike protein have received emergency use approval for treatment of COVID-19. However, with the emergence of variants of concern, there is a need for new treatment options. We report a format that enables modular assembly of bi-paratopic tetravalent nAbs with antigen-binding sites from two distinct nAbs. The tetravalent nAb purifies in high yield and exhibits biophysical characteristics that are comparable to those of clinically used therapeutic antibodies. The tetravalent nAb binds to the spike protein trimer at least 100-fold more tightly than bivalent IgGs (apparent KD < 1 pM) and neutralizes a broad array of SARS-CoV-2 pseudoviruses, chimeric viruses, and authentic viral variants with high potency. Together, these results establish the tetravalent diabody-Fc-Fab as a robust, modular platform for rapid production of drug-grade nAbs with potencies and breadth of coverage that greatly exceed those of conventional bivalent IgGs.

SUBMITTER: Miersch S 

PROVIDER: S-EPMC9108025 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies.

Miersch Shane S   Sharma Nitin N   Saberianfar Reza R   Chen Chao C   Caccuri Francesca F   Zani Alberto A   Caruso Arnaldo A   Case James Brett JB   Diamond Michael S MS   Amarasinghe Gaya K GK   Novelli Giuseppe G   Sidhu Sachdev S SS  

Cell reports 20220516 9

Neutralizing antibodies (nAbs) that target the SARS-CoV-2 spike protein have received emergency use approval for treatment of COVID-19. However, with the emergence of variants of concern, there is a need for new treatment options. We report a format that enables modular assembly of bi-paratopic tetravalent nAbs with antigen-binding sites from two distinct nAbs. The tetravalent nAb purifies in high yield and exhibits biophysical characteristics that are comparable to those of clinically used ther  ...[more]

Similar Datasets

Unknown Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.
| S-EPMC8020967 | biostudies-literature
Unknown Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants.
| S-EPMC11470419 | biostudies-literature
Unknown An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
| S-EPMC8828845 | biostudies-literature
Unknown Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants.
| S-EPMC9269068 | biostudies-literature
Unknown Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.
| S-EPMC9080080 | biostudies-literature
Unknown Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants.
| S-EPMC8255729 | biostudies-literature
Unknown Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD.
| S-EPMC8847360 | biostudies-literature
Unknown Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD.
| S-EPMC10833452 | biostudies-literature
Unknown Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers.
| S-EPMC8209050 | biostudies-literature
Unknown Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies.
| S-EPMC11228396 | biostudies-literature